Copay assistance

71 patient groups comment on nondiscrimination rule in healthcare

We, the undersigned 71 organizations, on behalf of millions of patients and American consumers who live with complex conditions such as HIV, autoimmune diseases, cancer, diabetes, lupus, hemophilia, mental illness, hepatitis, and neurological conditions write to comment on the Proposed Rulemaking for ACA Section 1557 Nondiscrimination in Health Programs and Activities. As detailed below, we are extremely pleased that you have taken meaningful steps to improve upon current regulations to ensure that people are not discriminated against in healthcare. In several instances, you have proposed to restore protections that had been included in the past but later withdrawn.  In other instances, you have provided further clarity on what constitutes discrimination.  In any instance, we emphasize that the law and whatever is finalized in regulation must be strictly enforced.

read more

Support for New York’s S.5299-A/A.1741-A on copay assistance

The HIV+Hepatitis Policy Institute is a leading HIV and hepatitis policy organization promoting quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions. We strongly support S.5299-A/A.1741-A, which would require health insurers to accept and count payments made on behalf of patients towards deductibles and out-of-pocket maximums. We urge you to sign this legislation into law as soon as possible.

read more

Support for D.C.’s “Copay Accumulator Amendment Act of 2021”

HIV+Hep strongly supports the “Copay Accumulator Amendment Act of 2021” (Bill 24-0557) introduced by Chairman Gray and four councilmembers.  It simply requires that the copay assistance beneficiaries receive count towards their out-of-pocket obligation.  By passing this law, DC will join 14 other states (Arkansas, Arizona, Connecticut, Georgia, Illinois, Kentucky, Louisiana, Maine, Oklahoma, North Carolina, Tennessee, Washington, West Virginia, and Virginia) and Puerto Rico in protecting consumers by assuring their copay assistance will count towards cost-sharing obligations.

read more

105 groups comment on the role of PBMs on patient access and affordability of prescription drugs

We, the undersigned 105 organizations, on behalf of millions of patients and Americans who live with complex conditions such as HIV, autoimmune diseases, cancer, diabetes, kidney disease, lupus, hemophilia, mental illness, and hepatitis write in response to the Federal Trade Commission (FTC) request for public comment on the impact of pharmacy benefit manager (PBM) practices on consumers.  Specifically, we offer comments on how PBMs impact the health and well-being of patients who receive their health coverage through the private insurance market.  While most people think insurers make the majority of decisions regarding health coverage and affordability, when it comes to prescription drugs, it is the PBMs that drive much of the decisions as to what medications a beneficiary can access and how much they pay for them.  We commend the FTC for its leadership to investigate the impact that PBM practices have on the patient communities we serve and believe this represents a critical step forward to improving patient access and affordability to necessary medications.

read more

Letter in support of Minnesota’s HF 3611 to require insurers to count copay assistance towards patient costs

The HIV+Hepatitis Policy Institute is a leading HIV and hepatitis policy organization promoting quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions. We strongly support House File 3611 which would require health insurers to accept and count payments made on behalf of patients towards deductibles and out-of-pocket maximums.

read more

Pin It on Pinterest